Status:
COMPLETED
Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients
Lead Sponsor:
Tanta University
Conditions:
Metabolic Associated Fatty Liver Disease
Pancreatic Steatosis
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to evaluate the prevalence of metabolic associated fatty liver disease (MAFLD), fatty pancreas and hepatic fibrosis in obese and lean patients with chronic hepatitis B; either treatme...
Detailed Description
Hepatitis B virus (HBV) infection is one of the major etiologies of chronic liver disease. Pathologies caused by HBV infection range from chronic hepatitis, fibrosis, cirrhosis, to hepatocellular carc...
Eligibility Criteria
Inclusion
- Age 18 years or older.
- Both sexes.
- Chronic hepatitis B patients.
Exclusion
- Hepatitis C virus (HCV) antibody positive.
- Hepatocellular carcinoma (HCC).
- Human immunodeficiency viruses (HIV).
- Pregnancy.
Key Trial Info
Start Date :
April 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT07175688
Start Date
April 10 2022
End Date
January 1 2024
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527